Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Receivables (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Receivables for 15 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 25.4% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a 25.4% increase, with the full-year FY2025 number at $9.7 million, up 25.4% from a year prior.
  • Receivables was $9.7 million for Q4 2025 at Niagen Bioscience, up from $8.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.7 million in Q1 2023 to a low of $2.8 million in Q4 2023.
  • A 5-year average of $7.3 million and a median of $7.3 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 59.41% in 2023, then surged 177.43% in 2024.
  • Niagen Bioscience's Receivables stood at $7.3 million in 2021, then decreased by 15.37% to $6.2 million in 2022, then crashed by 54.84% to $2.8 million in 2023, then skyrocketed by 177.43% to $7.8 million in 2024, then rose by 25.4% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Receivables are $9.7 million (Q4 2025), $8.5 million (Q3 2025), and $9.7 million (Q2 2025).